Compare NCMI & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NCMI | CHRS |
|---|---|---|
| Founded | 2005 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 207.0M | 177.7M |
| IPO Year | 2006 | 2014 |
| Metric | NCMI | CHRS |
|---|---|---|
| Price | $2.27 | $1.14 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $5.63 | $5.51 |
| AVG Volume (30 Days) | 861.8K | ★ 1.1M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.36% | N/A |
| EPS Growth | 52.17 | ★ 472.00 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.20 | $73.08 |
| Revenue Next Year | $6.22 | $30.94 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.11 | $1.09 |
| 52 Week High | $4.67 | $2.62 |
| Indicator | NCMI | CHRS |
|---|---|---|
| Relative Strength Index (RSI) | 36.79 | 37.82 |
| Support Level | $2.16 | N/A |
| Resistance Level | $3.72 | $1.53 |
| Average True Range (ATR) | 0.11 | 0.09 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 39.24 | 0.00 |
National CineMedia Inc is a cinema advertising platform in the U.S. It derives revenue from the sale of advertising to national, regional and local businesses through The Noovie Show and the CineLife Show, the cinema advertising and entertainment show seen on movie screens across the U.S., on LEN, a series of strategically-placed screens located in movie theater lobbies, as well as other forms of advertising and promotions in theater lobbies.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.